AstraZeneca announced a multi-billion-dollar expansion in China and struck a high-value collaboration to broaden its obesity and diabetes pipeline. The company committed more than $15 billion through 2030 to expand R&D and manufacturing capacity in China, a move management says will deepen local capabilities and accelerate drug development. The plan dovetails with a separate strategic deal with CSPC Pharmaceutical Group that gives AstraZeneca global rights to multiple next-generation weight-management candidates while preserving CSPC rights in Greater China. The CSPC agreement includes a reported $1.2 billion upfront payment and up to multi‑billion-dollar milestones and royalties, underscoring how multinationals are using large regional investments and licensing to secure fast followers in the competitive obesity market.